A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease

American Journal of Epidemiology

Volumn 162, Issue 11, 2005, Pages 1050-1061

  Cook, M B ^a   Wild, C P ^a   Forman, D ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Barrett esophagus; Female; Gastroesophageal reflux; Male; Meta analysis; Sex ratio

Indexed keywords

DISEASE PREVALENCE; SEX RATIO;

AGE DISTRIBUTION; BARRETT ESOPHAGUS; CANCER RISK; COLUMNAR EPITHELIUM; COMPARATIVE STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS MUCOSA; GASTROESOPHAGEAL REFLUX; GENETIC SUSCEPTIBILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; INTESTINE METAPLASIA; PREGNANCY; REFLUX ESOPHAGITIS; REVIEW; RISK FACTOR; SAMPLE SIZE; SEX DIFFERENCE; SYSTEMATIC REVIEW;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; BARRETT ESOPHAGUS; COHORT STUDIES; COMORBIDITY; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SEX DISTRIBUTION; WORLD HEALTH;

EID: 28544435347     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwi325     Document Type: Review

References (102)

1. Cameron AJ, Zinsmeister AR, Ballard DJ, et al. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990;99:918-22.
2. Spechler SJ, Goyal RK. Barrett's esophagus. N Engl J Med 1986;315:362-71.
3. Conio M, Filiberti R, Blanchi S, et al. Risk factors for Barrett's esophagus: a case-control study. Int J Cancer 2002;97:225-9.
4. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol 1997;92:1293-7.
5. Eisen GM, Sandler RS, Murray S, et al. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol 1997;92:27-31.
6. Spechler SJ. Clinical practice. Barrett's esophagus. N Engl J Med 2002;346:836-42.
7. Kulig M, Nocon M, Vieth M, et al. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol 2004;57:580-9.
8. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976;21:953-6.
9. Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann Med 1995;27:67-70.
10. Louis E, DeLooze D, Deprez P, et al. Heartburn in Belgium: prevalence, impact on daily life, and utilization of medical resources. Eur J Gastroenterol Hepatol 2002;14:279-84.
11. Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology 1996;110:614-21.
12. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
13. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 2003;3:676-84.
14. Caygill CP, Watson A, Reed PI, et al. Characteristics and regional variations of patients with Barrett's oesophagus in the UK. Eur J Gastroenterol Hepatol 2003;15:1217-22.
15. Parrilla P, Martinez de Haro LF, Ortiz A, et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 2003;237:291-8.
16. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002;123:461-7.
17. El-Serag HB, Garewel H, Kuebeler M, et al. Is the length of newly diagnosed Barrett's esophagus decreasing? The experience of a VA Health Care System. Clin Gastroenterol Hepatol 2004;2:296-300.
18. StataCorp. Stata statistical software: release 8.2. College Station, TX: StataCorp LP, 2004.
19. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
20. Sharp SJ. Meta-analysis regression. In: Stata technical bulletin. College Station, TX: StataCorp LP, 1998:16-22.
21. Bollschweiler E, Wolfgarten E, Gutschow C, et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001;92:549-55.
22. Kubo A, Corley DA. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer 2002;95:2096-102.
23. Vizcaino AP, Moreno V, Lambert R, et al. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002;99:860-8.
24. Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9.
25. Ford AC, Forman D, Reynolds PD, et al. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol 2005;162:454-60.
26. Hillman LC, Chiragakis L, Clarke AC, et al. Barrett's esophagus: macroscopic markers and the prediction of dysplasia and adenocarcinoma. J Gastroenterol Hepatol 2003;18:526-33.
27. Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000;92:1316-21.
28. Anderson LA, Murray LJ, Murphy SJ, et al. Mortality in Barrett's oesophagus: results from a population based study. Gut 2003;52:1081-4.
29. Solaymani-Dodaran M, Coupland C, Logan FA. Risk of oesophageal cancer in Barrett's oeosphagus and in gastrooesophageal reflux. (Abstract). Gastroenterology 2003;124:A33.
30. Cooper BT, Barbezat GO. Barrett's oesophagus: a clinical study of 52 patients. Q J Med 1987;62:97-108.
31. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
32. McDougall NI, Johnston BT, Collins JS, et al. Three- to 4.5-year prospective study of prognostic indicators in gastrooesophageal reflux disease. Scand J Gastroenterol 1998;33:1016-22.
33. Pace F, Porro GB. Gastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed). Am J Gastroenterol 2004;99:946-9.
34. Fass R, Ofman JJ. Gastroesophageal reflux disease-should we adopt a new conceptual framework? Am J Gastroenterol 2002;97:1901-9.
35. Richter JE, Baldi F, Clouse R, et al. Functional esophageal disorders. In: Drossman DA, ed. Functional gastrointestinal disorders. Boston, MA: Little, Brown, 1994:25-70.
36. Galmiche JP, Scarpignato C. Oesophageal sensitivity to acid in patients with non-cardiac chest pain: is the oesophagus hypersensitive? Eur J Gastroenterol Hepatol 1995;7:1152-9.
37. Shi G, Tatum RP, Joehl RJ, et al. Esophageal sensitivity and symptom perception in gastroesophageal reflux disease. Curr Gastroenterol Rep 1999;1:214-19.
38. Quigley EM. Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities? Best Pract Res Clin Gastroenterol 2004;18:695-706.
39. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol 2001;96:303-14.
40. Pehlivanov ND, Liu J, Mittal R. Sustained esophageal contraction: a motor correlate of heartburn symptom. (Abstract). Gastroenterology 1999;116:G4613.
41. Fass R, Naliboff B, Higa L, et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 1998;115:1363-73.
42. Agreus L, Svardsudd K, Nyren O, et al. The epidemiology of abdominal symptoms: prevalence and demographic characteristics in a Swedish adult population. A report from the Abdominal Symptom Study. Scand J Gastroenterol 1994; 29:102-9.
43. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569-80.
44. Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000;14:1589-94.
45. Wong WM, Lai KC, Lam KF, et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther 2003;18:595-604.
46. Bolin TD, Korman MG, Hansky J, et al. Heartburn: community perceptions. J Gastroenterol Hepatol 2000;15:35-9.
47. Zaman MS, Robson K, Rosenberg S, et al. The development of dysplasia on follow-up endoscopy among patients with short segment Barrett's esophagus: a cohort of 61 patients followed for a mean of 30 months. (Abstract). Gastrointest Endosc 2001;51:AB115.
48. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999;94:2037-42.
49. Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001;48:304-9.
50. Campos GM, DeMeester SR, Peters JH, et al. Predictive factors of Barrett esophagus: multivariate analysis of 502 patients with gastroesophageal reflux disease. Arch Surg 2001;136:1267-73.
51. Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000;132:612-20.
52. Cotton JP, Lopez M, McLead S, et al. Gender differences in the epidemiology of GORD. (Abstract). Gut 2003;52:A46.
53. Pereira AD, Chaves P, Suspiro A, et al. Risk of neoplastic progression in Barrett's esophagus: data from a prospective surveillance program in Portugal. (Abstract). Gastroenterology 2003;124:A635.
54. Conio M, Blanchi S, Lapertosa G, et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003;98:1931-9.
55. de Mas CR, Kramer M, Seifert E, et al. Short Barrett: prevalence and risk factors. Scand J Gastroenterol 1999;34:1065-70.
56. Grunewald M, Vieth M, Kreibich H, et al. Current diagnosis of Barrett's oesophagus: an analysis of 1000 histologically confirmed cases. (In German). Dtsch Med Wochenschr 1997;122:427-31.
57. Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease - an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003;18:767-76.
58. Harle IA, Finley RJ, Belsheim M, et al. Management of adenocarcinoma in a columnar-lined esophagus. Ann Thorac Surg 1985;40:330-6.
59. Williamson WA, Ellis FH Jr, Gibb SP, et al. Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med 1991;151:2212-16.
60. Sampliner RE, Eisen GM, De Garmo P. Ethnicity and gender of patients with suspected Barrett's esophagus in a large endoscopy cohort (CORI). (Abstract). Gastrointest Endosc 2001;53:AB151.
61. Csendes A, Smok G, Cerda G, et al. Prevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's esophagus. Dis Esophagus 1997;10:38-42.
62. Csendes A, Smok G, Burdiles P, et al. Prevalence of intestinal metaplasia according to the length of the specialized columnar epithelium lining the distal esophagus in patients with gastroesophageal reflux. Dis Esophagus 2003;16:24-8.
63. Wright TA, Gray MR, Morris AI, et al. Cost effectiveness of detecting Barrett's cancer. Gut 1996;39:574-9.
64. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 2000;321:1252-5.
65. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991;32:1441-6.
66. Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med 2001;111:33-7.
67. Hameeteman W, Tytgat GN, Houthoff HJ, et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-56.
68. van der Burgh A, Dees J, Hop WC, et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:5-8.
69. Nilsson J, Skobe V, Johansson J, et al. Screening for oesophageal adenocarcinoma: an evaluation of a surveillance program for columnar metaplasia of the oesophagus. Scand J Gastroenterol 2000;35:10-16.
70. Thomson AB, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003;17:1481-91.
71. Robinson M, Fitzgerald S, Hegedus R, et al. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 2002;16:445-54.
72. El-Serag HB, Johanson JF. Risk factors for the severity of erosive esophagitis in Helicobacter pylori-negative, patients with gastroesophageal reflux disease. Scand J Gastroenterol 2002;37:899-904.
73. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-73.
74. Neumann CS, Cooper BT. Ethnic differences in gastrooesophageal reflux disease. Eur J Gastroenterol Hepatol 1999;11:735-9.
75. O'Connor HJ, Cunnane K. Helicobacter pylori and gastrooesophageal reflux disease - a prospective study. Ir J Med Sci 1994;163:369-73.
76. Mantynen T, Farkkila M, Kunnamo I, et al. The impact of upper GI endoscopy referral volume on the diagnosis of gastroesophageal reflux disease and its complications: a 1-year cross-sectional study in a referral area with 260,000 inhabitants. Am J Gastroenterol 2002;97:2524-9.
77. Schilling D, Kudis V, Riemann F. Natural course of erosive reflux disease: results of a prospective study with a mean follow-up of 6 years. (Abstract). Gastroenterology 2003;124:A641.
78. Hackelsberger A, Schultze V, Gunther T, et al. The prevalence of Helicobacter pylori gastritis in patients with reflux oesophagitis: a case-control study. Eur J Gastroenterol Hepatol 1998;10:465-8.
79. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999;117:11-16.
80. Jaspersen D, Kulig M, Labenz J, et al. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther 2003;17:1515-20.
81. Frazzoni M, De Micheli E, Savarino V. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease. Aliment Pharmacol Ther 2003;18:1091-8.
82. Loffeld R, Van Der Putten A. Rising incidence of reflux oesophagitis in patients undergoing upper gastrointestinal endoscopy. Digestion 2003;68:141-4.
83. Garrido Serrano A, Guerrero Igea FJ, Lepe Jimenez JA, et al. Clinical features and endoscopic progression of gastroesophageal reflux disease. Rev Esp Enferm Dig 2003;95:712-16.
84. Cronstedt J, Carling L, Vestergaard P, et al. Oesophageal disease revealed by endoscopy in 1,000 patients referred primarily for gastroscopy. Acta Med Scand 1978;204:413-16.
85. Nilsson M, Lundegardh G, Carling L, et al. Body mass and reflux oesophagitis: an oestrogen-dependent association? Scand J Gastroenterol 2002;37:626-30.
86. Loof L, Gotell P, Elfberg B. The incidence of reflux oesophagitis. A study of endoscopy reports from a defined catchment area in Sweden. Scand J Gastroenterol 1993;28:113-18.
87. Koelz HR, Birchler R, Bretholz A, et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology 1986;91:1198-205.
88. Csendes A, Smok G, Burdiles P, et al. Prevalence of Barrett's esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. Dis Esophagus 2000;13:5-11.
89. Csendes A, Maluenda F, Braghetto I, et al. Location of the lower oesophageal sphincter and the squamous columnar mucosal junction in 109 healthy controls and 778 patients with different degrees of endoscopic oesophagitis. Gut 1993;34:21-7.
90. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. Am J Gastroenterol 1999;94:3468-72.
91. Fujimoto K, Iwakiri R, Okamoto K, et al. Characteristics of gastroesophageal reflux disease in Japan: increased prevalence in elderly women. J Gastroenterol 2003;38:3-6.
92. Yeom JS, Park HJ, Cho JS, et al. Reflux esophagitis and its relationship to hiatal hernia. J Korean Med Sci 1999;14:253-6.
93. Lee SJ, Song CW, Jeen YT, et al. Prevalence of endoscopic reflux esophagitis among Koreans. J Gastroenterol Hepatol 2001;16:373-6.
94. Kang JY, Tay HH, Yap I, et al. Low frequency of endoscopic esophagitis in Asian patients. J Clin Gastroenterol 1993;16:70-3.
95. Yeh C, Hsu CT, Ho AS, et al. Erosive esophagitis and Barrett's esophagus in Taiwan: a higher frequency than expected. Dig Dis Sci 1997;42:702-6.
96. Miner P Jr, Orr W, Filippone J, et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002;97:1332-9.
97. Damiano A, Siddique R, Xu X, et al. Reductions in symptom distress reported by patients with moderately severe, non-erosive gastroesophageal reflux disease treated with rabeprazole. Dig Dis Sci 2003;48:657-62.
98. Richter JE, Peura D, Benjamin SB, et al. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 2000;160:1810-16.
99. Richter JE, Campbell DR, Kahrilas PJ, et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000;160:1803-9.
100. Bate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996;10:547-55.
101. Voutilainen M, Sipponen P, Mecklin JP, et al. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion 2000;61:6-13.
102. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-9.